ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: SA-OR004

Clinical Utility and Interpretation of CKD Stages in Living Kidney Donors

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Massie, Allan, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
  • Thomas, Alvin G., UNC Chapel HIll, Chapel Hill, North Carolina, United States
  • Snyder, Jon J., Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States
  • Segev, Dorry L., Johns Hopkins University, Baltimore, Maryland, United States

Current definitions of chronic kidney disease (CKD) staging define any individual with estimated glomerular filtration rate (eGFR)<60 as having stage 3 or higher CKD. Nearly half of living kidney donors (LKDs) have post-donation eGFR below this threshold, but the clinical interpretation of eGFR<60 in donors is unknown, and the "CKD" label may not be appropriate. Evidence of risk associated with decreased post-donation eGFR is needed to inform international guidelines and best practices for donor followup and care management.


Using national registry data, we studied end-stage renal disease (ESRD) risk in 67,571 LKDs 1999-2015 with at least one reported postdonation serum creatinine (SCr). eGFR was calculated via the CKD-EPI equation. Measurements with eGFR<15 were excluded from analysis. We modeled the association between eGFR category (≥60, 45-59, 30-44, 15-30, corresponding to no CKD, CKD stage 3, stage 4A, and stage 4B) using Cox regression with eGFR category as a time-varying exposure and adjusting for donor age, sex, race (black vs nonblack), BMI, and 1st-degree biological relationship to recipient.


117,051 CKD measurements were reported at median (IQR) 11 (4-14) months post-donation (90th percentile 25m post-donation). Of these, 33.9% were in the range 45-59, 5.7% were in the range 30-45, and 0.8% were in the range 15-29. Lower eGFR categories were associated with greater ESRD risk: 5-fold higher risk for eGFR 30-45 (aHR = 5.3 (2.1-13.3)) and 54-fold higher risk for eGFR 15-29 (aHR=53.7 (4.8-421.3); both p<0.001). Donors with eGFR 45-60 had elevated risk but the association was not statistically significant (aHR=1.9 (0.9-3.8), p=0.08).


There is insufficient evidence to support the category eGFR 45-60 as clinically meaningful "CKD stage 3" among LKDs. Nevertheless, eGFR category is associated with ESRD risk among donors with eGFR<45, and our results support current guidelines recommending longitudinal followup of renal function in living kidney donors.


  • NIDDK Support